Welcome to LookChem.com Sign In|Join Free

CAS

  • or
BICYCLO[2.2.2]OCTANE-1,4-DICARBOXYLIC ACID HEMIMETHYL ESTER is a complex organic compound characterized by its bicyclic octane structure and ester functional groups. It is known for its unique chemical properties and potential applications in various industries.

18720-35-9

Post Buying Request

18720-35-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

18720-35-9 Usage

Uses

Used in Pharmaceutical Industry:
BICYCLO[2.2.2]OCTANE-1,4-DICARBOXYLIC ACID HEMIMETHYL ESTER is used as a reactant for the preparation of bicyclo-octyltriazole inhibitors of HSD1. These inhibitors are crucial for the treatment of metabolic syndrome, a cluster of conditions that increase the risk of heart disease, stroke, and type 2 diabetes.
Used in Chemical Synthesis:
BICYCLO[2.2.2]OCTANE-1,4-DICARBOXYLIC ACID HEMIMETHYL ESTER can be utilized as an intermediate in the synthesis of various complex organic molecules, contributing to the development of new compounds with potential applications in different fields, such as pharmaceuticals, materials science, and agrochemicals.
Used in Research and Development:
Due to its unique structure and properties, BICYCLO[2.2.2]OCTANE-1,4-DICARBOXYLIC ACID HEMIMETHYL ESTER can be employed in research and development for exploring new chemical reactions, understanding reaction mechanisms, and discovering novel applications in various industries.

Check Digit Verification of cas no

The CAS Registry Mumber 18720-35-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,8,7,2 and 0 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 18720-35:
(7*1)+(6*8)+(5*7)+(4*2)+(3*0)+(2*3)+(1*5)=109
109 % 10 = 9
So 18720-35-9 is a valid CAS Registry Number.
InChI:InChI=1/C11H16O4/c1-15-9(14)11-5-2-10(3-6-11,4-7-11)8(12)13/h2-7H2,1H3,(H,12,13)

18720-35-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-(Methoxycarbonyl)bicyclo[2.2.2]octane-1-carboxylic acid

1.2 Other means of identification

Product number -
Other names 4-methoxycarbonylbicyclo[2.2.2]octane-1-carboxylic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:18720-35-9 SDS

18720-35-9Relevant articles and documents

Bicyclo [2.2.2] octane - 1, 4 - dicarboxylic acid mono methyl ester synthesis method

-

Paragraph 0007; 0024; 0025; 0026; 0027; 0036; 0037, (2017/07/07)

The invention relates to a synthetic method of an organic compound. The synthetic method of bicyclo-[2.2.2]octane-1,4-dicarboxylic acid monomethyl easter is as follows: firstly, adopting sodium hydride, DMSS and 1,2-dibromoethane to synthesize the intermediate I; secondly, adopting the intermediate I, sodium acetate, ammourea hydrochloride and alcohol to synthesize semicarbazon; thirdly, adopting potassium hydroxide, diethylene glycol and semicarbazon to synthesize target diacid; fourthly, adopting target diacid, thionyl chloride and methanol to synthesize target diester; and fifthly, adopting target diester, potassium hydroxide and 95% of methanol water solution to synthesize the target product monoester. The invention has reasonable synthetic process route, mild process conditions, environment friendly, easy operation, low raw material cost, high product yield and excellent purity, and is applicable to industrial production and satisfies the application requirement of each industry.

POLYMERIZABLE COMPOUND AND OPTICAL ANISOTROPIC BODY

-

Paragraph 0202-0204, (2018/01/02)

PROBLEM TO BE SOLVED: To provide a polymerizable composition that causes few orientation defects when added to a polymerizable composition and making a film-like polymer, and is resistant to discoloration when put in a high temperature condition. SOLUTION: The present invention provides a compound illustrated by the formula (I-6), a polymerizable composition containing the compound, a polymer obtained by the polymerization of the composition, and an optical anisotropic body prepared with the polymer. SELECTED DRAWING: None COPYRIGHT: (C)2018,JPO&INPIT

Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors

-

Page/Page column 527; 528, (2016/03/19)

The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.

Design and synthesis of novel 19F-amino acid: A promising 19F NMR label for peptide studies

Bandak, Dmytro,Babii, Oleg,Vasiuta, Roman,Komarov, Igor V.,Mykhailiuk, Pavel K.

supporting information, p. 226 - 229 (2015/03/05)

Novel aliphatic 19F-substituted amino acid was designed as a 19F NMR label for peptide studies. The synthesis was performed in 11 steps and 9% overall yield from a commercially available starting material. The key transformation was a decarboxylative fluorination of an aliphatic carboxylic acid with XeF2 in C6F6.

COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS

-

Page/Page column 467; 468, (2015/02/02)

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Discovery of functionalized bisimidazoles bearing cyclic aliphatic-phenyl motifs as HCV NS5A inhibitors

Zhong, Min,Peng, Eric,Huang, Ningwu,Huang, Qi,Huq, Anja,Lau, Meiyen,Colonno, Richard,Li, Leping

, p. 5731 - 5737 (2015/01/08)

This Letter describes the discovery of a number of functionalized bisimidazoles bearing a cyclohexylphenyl, piperidylphenyl, or bicyclo[2,2,2]octylphenyl motif as HCV NS5A inhibitors. Compounds 2c, 4b and 6 have demonstrated low single-digit nM potency in gt-1a replicon and double-digit pM potency in gt-1b replicon, respectively. Moreover, both 4b and 6 have, respectively, exhibited good oral bioavailability in rats with a favorable liver/plasma ratio of the drug concentration.

BICYCLO [2.2.2] ACID GPR120 MODULATORS

-

Paragraph 00189, (2014/10/15)

The present invention provides compounds of Formula (I) or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be use

SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS

-

Paragraph 1268; 1287, (2014/09/29)

Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.

BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS

-

Page/Page column 64, (2013/03/26)

Novel bridged bicyclic compounds are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antibacterial agents. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating bacterial infections and associated diseases and conditions.

SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

-

Page/Page column 135, (2012/11/07)

Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 18720-35-9